Skip to main content
. 2021 Jan;18(1):75–83. doi: 10.1513/AnnalsATS.202002-144OC

Figure 2.

Figure 2.

Mean absolute change from baseline in clinical measures at 1, 3, 6, and 12 months after initiation of lumacaftor/ivacaftor. The bars represent the 95% confidence intervals. (A) Sweat chloride (in mmol/L). (B) ppFEV1. (C) FEV1 (in liters). (D) Body mass index (BMI) percentile (n = 125 subjects < 20 yr of age). (E) BMI (in kg/m2) (n = 68 subjects ≥ 20 yr of age). FEV1 = forced expiratory volume in 1 second; ppFEV1 = percent-predicted FEV1; SwtCl = sweat chloride.